Preferred Label : Ensifentrine;
NCIt definition : An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with
potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine
targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular
levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.
This may lead to bronchial smooth muscle relaxation and modulate inflammatory responses.
PDE3 and PDE4, members of the PDE superfamily, hydrolyze cAMP and 3',5'-cyclic guanosine
monophosphate (cGMP) to their inactive 5' monophosphates. PDE3 is the most expressed
PDE isoenzyme in bronchial smooth muscle. PDE4 is expressed in immune cells including
T-cells, monocytes, macrophages, neutrophils, dendritic cells and eosinophils. It
plays an important role in inflammation, especially in inflammatory airway diseases.;
UNII : 3E3D8T1GIX;
InChIKey : CSOBIBXVIYAXFM-BYNJWEBRSA-N;
CAS number : 1884461-72-6;
Molecule name : RPL 554; RPL-554;
NCI Metathesaurus CUI : CL971923;
Origin ID : C166674;
UMLS CUI : C1744503;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
